Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Three-Part Phase 1b Bioavailability and Pharmacokinetics Study of Two Formulations of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis

NCT02767297 is registered in ClinicalTrials.gov with Flatley Discovery Lab LLC as lead sponsor.

NCT NCT02767297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02767297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Three-Part Phase 1b Bioavailability and Pharmacokinetics Study of Two Formulations of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis
Lead sponsor
Flatley Discovery Lab LLC
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2016
Completion date
October 31, 2016
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis